| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
There is no specific pharmacological receptor target; the mPEG layer creates a steric barrier that reduces opsonization and complement activation, while the DSPE lipid anchor inserts into lipid bilayers; DSPE-mPEG-2000 is used to create hydrophilic steric barriers on liposome surfaces, improving colloidal stability and circulatory half-life.
|
|---|---|
| ln Vitro |
In vitro, DSPE-mPEG-modified liposomes show reduced protein adsorption and complement activation compared with non-PEGylated liposomes; the PEG layer reduces macrophage uptake in cell culture, and the cytotoxicity of liposome-entrapped payloads depends on the surface charge and density of DSPE-mPEG, with higher PEG density generally reducing nonspecific cellular uptake.
|
| ln Vivo |
In vivo, DSPE-mPEG significantly prolongs the circulatory half-life of liposomes and lipid nanoparticles by reducing opsonization and macrophage clearance; it enhances accumulation in target tissues through the enhanced permeability and retention effect, and is a key component of stealth liposomes and mRNA lipid nanoparticles, improving pharmacokinetics and tolerability.
|
| Enzyme Assay |
DSPE-mPEG is characterized physicochemically rather than by enzyme or receptor binding; methods include dynamic light scattering for particle size and zeta potential, fluorescence-based protein adsorption assays (e.g., BSA adsorption), complement activation assays (CH50 or C3a ELISA), and HPLC for PEG-lipid quantification; critical micelle concentration is measured by surface tension or fluorescent probe methods.
|
| Cell Assay |
Macrophages or cancer cell lines are incubated with DSPE-mPEG-containing liposomes at defined lipid concentrations for 4–48 h; cellular uptake is quantified by flow cytometry or confocal microscopy using fluorescently labeled liposomes, cytotoxicity is measured by metabolic activity assays, and complement activation is assessed by C3a ELISA in serum-containing media.
|
| Animal Protocol |
Mice or rats receive DSPE-mPEG-modified liposomes or lipid nanoparticles by intravenous injection at doses selected from tolerability studies; blood samples are collected at serial time points for pharmacokinetic analysis of the liposome or payload, tissue biodistribution is assessed by fluorescence or radiolabel imaging, and toxicity is monitored by body weight, serum biochemistry, and histopathology.
|
| References |
|
| Molecular Formula |
(C2H4O)NC43H84NO10P
|
|---|---|
| Molecular Weight |
872.136
|
| Exact Mass |
871.591
|
| CAS # |
156543-00-9
|
| Related CAS # |
18:0 mPEG2000 PE ammonium;474922-77-5
|
| PubChem CID |
86278269
|
| Appearance |
White to off-white solid
|
| tPSA |
159
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
48
|
| Heavy Atom Count |
59
|
| Complexity |
994
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC.[Na+]
|
| InChi Key |
SRLOHQKOADWDBV-NRONOFSHSA-M
|
| InChi Code |
InChI=1S/C45H88NO11P.Na/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-43(47)54-40-42(41-56-58(50,51)55-37-36-46-45(49)53-39-38-52-3)57-44(48)35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-2;/h42H,4-41H2,1-3H3,(H,46,49)(H,50,51);/q;+1/p-1/t42-;/m1./s1
|
| Chemical Name |
sodium;[(2R)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1466 mL | 5.7330 mL | 11.4660 mL | |
| 5 mM | 0.2293 mL | 1.1466 mL | 2.2932 mL | |
| 10 mM | 0.1147 mL | 0.5733 mL | 1.1466 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.